NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study

Reuters

10/20

NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study

NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology (ESMO) Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma $(RCC)$ patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-243050), on October 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576785960"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576785960\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576785960?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576785960","market":"fut","top_or_hot":-1,"title":"NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology (ESMO) Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma <a href=\"https://laohu8.com/S/RCC\">$(RCC)$</a> patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-243050), on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-20 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology (ESMO) Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma <a href=\"https://laohu8.com/S/RCC\">$(RCC)$</a> patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-243050), on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NCNA","symbol_name":"Nucana PLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL6mg3Qh:1","article_id":"2576785960","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576785960","pubTimestamp":1760961686,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology  Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma  patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NCNA":"Nucana PLC","BK4139":"生物科技"},"translate_title":"NuCana报告NUC-7738联合PD-1抑制剂在癌症研究中取得有希望的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NCNA":0.9},"content_text":"NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study\n    \n\n        NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology (ESMO) Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma $(RCC)$ patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-243050), on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}